These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39359732)

  • 1. Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial.
    Liu J; Bai S; Sun Y; Hu L; Ge R; Xue F
    Front Immunol; 2024; 15():1449211. PubMed ID: 39359732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
    Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
    Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
    Kim RD; Sanoff HK; Poklepovic AS; Soares H; Kim J; Lyu J; Liu Y; Nixon AB; Kim DW
    Cancer; 2020 Aug; 126(15):3464-3470. PubMed ID: 32453456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
    Tan Y; Liu K; Zhu C; Wang S; Wang Y; Xue J; Ning C; Zhang N; Chao J; Zhang L; Long J; Yang X; Zeng D; Zhao L; Zhao H
    Cancer Immunol Immunother; 2024 Oct; 73(12):240. PubMed ID: 39358463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis.
    Zhou J; Li J; Fan Z; Lv G; Wang G
    Front Immunol; 2024; 15():1378760. PubMed ID: 38840927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
    Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE).
    Ueno M; Morizane C; Ikeda M; Ozaka M; Nagashima F; Kataoka T; Mizusawa J; Ohba A; Kobayashi S; Imaoka H; Kasuga A; Okano N; Nagasaka Y; Sasaki M; Furuse J; Okusaka T
    ESMO Open; 2024 Oct; 9(10):103919. PubMed ID: 39353216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
    An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
    Clin Transl Oncol; 2024 Aug; 26(8):2006-2019. PubMed ID: 38530557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
    Cousin S; Cantarel C; Guegan JP; Mazard T; Gomez-Roca C; Metges JP; Bellera C; Adenis A; Korakis I; Poureau PG; Bourcier K; Toulmonde M; Kind M; Rey C; Auzanneau C; Bessede A; Soubeyran I; Italiano A
    Eur J Cancer; 2022 Feb; 162():161-169. PubMed ID: 34998048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
    Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
    Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer.
    Zhao S; Guo XG; Zhang D; Zhou G; Song P; Yang J; Zhang Y; Li P; Hu Y; Wang P
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3541-3547. PubMed ID: 34423859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer.
    Pressiani T; Balsano R; Giordano L; Milella M; Bergamo F; Bozzarelli S; Noventa S; Ferrrari D; Scartozzi M; Parra HS; Auriemma A; Soldà C; Zaniboni A; Zecchetto C; Rizzato MD; Rimassa L; Santoro A
    Eur J Cancer; 2024 Aug; 207():114196. PubMed ID: 38954899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.